ELISA/assay

Porcine Fibroblast Growth Factor 23 ELISA Kit

MBS028021

96 Strip Wells

600 USD

ELISA Kit

Porcine Fibroblast Growth Factor 23 ELISA Kit

Fibroblast Growth Factor 23

fibroblast growth factor 23; Fibroblast growth factor 23; fibroblast growth factor 23; phosphatonin; tumor-derived hypophosphatemia inducing factor; fibroblast growth factor 23; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor

FGF-23

FGF23; FGF23; ADHR; FGFN; HYPF; HPDR2; PHPTC; HYPF; FGF-23

FGF23_HUMAN

Porcine

No significant cross-reactivity or interference between Porcine FGF-23 and analogues was observed.

Store all reagents at 2-8 degree C

Samples: Serum, Plasma, Tissue Homogenate, Feces, Urine and Body Fluids. Intended Uses: This Quantitative Sandwich ELISA kit is only for in vitro research use only, not for drug, household, therapeutic or diagnostic applications! It is intended to be determinated FGF-23 concentrations in Porcine serum, plasma and other body fluids. Using Purified Porcine FGF-23 antibody to coat Microelisa Stripplate wells to make solid-phase antibody, then add FGF-23 and FGF-23 antibody which has been labeled with HRP to wells, then the reactants become antibody-antigen-antibody-enzyme complex, after washing completely, add TMB substrate solution, TMB substrate becomes blue color under HRP enzyme-catalyzed, reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm. The concentration of FGF-23 in the samples is then determined by comparing the O.D. of the samples to the standard curve. Detection Range: The detection range of this kit is 31.2 pg/ml - 1000 pg/ml.

Sensitivity: The sensitivity of this kit is 5.0 pg/ml. Intra-assay Precision: Intra-assay CV (%) is less than 15%. Inter-assay Precision: Inter-assay CV (%) is less than 15%. [CV(%) = SD/mean ×100]

Background: This Quantitative Sandwich ELISA kit is only for in vitro research use only, not for drug, household, therapeutic or diagnostic applications! It is intended to be determinated FGF-23 concentrations in Porcine serum, plasma and other body fluids. Using Purified Porcine FGF-23 antibody to coat Microelisa Stripplate wells to make solid-phase antibody, then add FGF-23 and FGF-23 antibody which has been labeled with HRP to wells, then the reactants become antibody-antigen-antibody-enzyme complex, after washing completely, add TMB substrate solution, TMB substrate becomes blue color under HRP enzyme-catalyzed, reaction is terminated by the addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm. The concentration of FGF-23 in the samples is then determined by comparing the O.D. of the samples to the standard curve.

10190674

NP_065689.1

NM_020638.2

Q9GZV9

27,954 Da

Activated Point Mutants Of FGFR2 Pathway 645281!!Adaptive Immune System Pathway 366160!!Constitutive PI3K/AKT Signaling In Cancer Pathway 685535!!DAP12 Interactions Pathway 685549!!DAP12 Signaling Pathway 685550!!Disease Pathway 530764!!Downstream Signaling Events Of B Cell Receptor (BCR) Pathway 576250!!Downstream Signal Transduction Pathway 106385!!Downstream Signaling Of Activated FGFR Pathway 160957!!FGF Signaling Pathway 137989

This gene encodes a member of the fibroblast growth factor family of proteins, which possess broad mitogenic and cell survival activities and are involved in a variety of biological processes. The product of this gene regulates phosphate homeostasis and transport in the kidney. The full-length, functional protein may be deactivated via cleavage into N-terminal and C-terminal chains. Mutation of this cleavage site causes autosomal dominant hypophosphatemic rickets (ADHR). Mutations in this gene are also associated with hyperphosphatemic familial tumoral calcinosis (HFTC). [provided by RefSeq, Feb 2013]

Function: Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL . By similarity. Acts directly on the parathyroid to decrease PTH secretion . By similarity. Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization. Ref.2 Ref.8 Ref.13 Ref.14 Ref.16. Subunit structure: Interacts with FGFR1, FGFR2, FGFR3 and FGFR4. Affinity between fibroblast growth factors (FGFs) and their receptors is increased by KL and heparan sulfate glycosaminoglycans that function as coreceptors . By similarity. Ref.14. Subcellular location: Secreted. Note: Secretion is dependent on O-glycosylation. Ref.15. Tissue specificity: Expressed in osteogenic cells particularly during phases of active bone remodeling. In adult trabecular bone, expressed in osteocytes and flattened bone-lining cells (inactive osteoblasts). Ref.11. Post-translational modification: Following secretion this protein is inactivated by cleavage into a N-terminal fragment and a C-terminal fragment. The processing is effected by proprotein convertases.O-glycosylated by GALT3. Glycosylation is necessary for secretion; it blocks processing by proprotein convertases when the O-glycan is alpha 2,6-sialylated. Competition between proprotein convertase cleavage and block of cleavage by O-glycosylation determines the level of secreted active FGF23. Ref.15. Involvement in disease: Hypophosphatemic rickets, autosomal dominant (ADHR) [MIM:193100]: A disease characterized by isolated renal phosphate wasting, hypophosphatemia, and inappropriately normal 1,25-dihydroxyvitamin D3 (calcitriol) levels. Patients frequently present with bone pain, rickets, and tooth abscesses.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.2 Ref.8 Ref.15Tumoral calcinosis, hyperphosphatemic, familial (HFTC) [MIM:211900]: A severe metabolic disorder that manifests with hyperphosphatemia and massive calcium deposits in the skin and subcutaneous tissues. Some patients manifest recurrent, transient, painful swellings of the long bones associated with the radiographic findings of periosteal reaction and cortical hyperostosis and absence of skin involvement.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.19. Sequence similarities: Belongs to the heparin-binding growth factors family.

96 Strip Wells

600 USD